A Randomized, Placebo-controlled, Double-blind, Phase II Chemoprevention Clinical Trial of Topical Diclofenac and DFMO in Subjects with a History of Skin Cancer
Latest Information Update: 17 Dec 2024
At a glance
- Drugs Diclofenac/hyaluronic-acid (Primary) ; Eflornithine (Primary)
- Indications Actinic keratosis; Skin cancer
- Focus Therapeutic Use
Most Recent Events
- 13 Dec 2024 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
- 13 Dec 2024 Planned primary completion date changed from 1 Nov 2024 to 1 Nov 2025.
- 20 Dec 2023 Planned primary completion date changed from 1 Nov 2023 to 1 Nov 2024.